Abstract
Novel probiotic S. boulardii yeast strain evolved through non-genetic engineering methods to produce compounds that improve glucose metabolism and insulin sensitivity.
Background
Metabolic disorders including insulin resistance and impaired glucose metabolism affect millions globally. Current interventions typically involve:
- Pharmaceutical approaches with potential side effects
- Dietary restrictions that are difficult to maintain long-term
- Supplements with variable efficacy and limited targeted delivery
Natural solutions that can deliver consistent active compounds directly to the intestinal target site represent a significant opportunity for metabolic health improvement.
Our Innovation
This adaptively evolved probiotic yeast offers:
- Non-GMO Approach: Uses Adaptive Laboratory Evolution rather than genetic engineering
- Targeted Active Compounds: Produces molecules that specifically improve liver glucose metabolism
- Validated Efficacy: Demonstrated reduced insulin resistance in mouse models
- Continuous Delivery: Ensures consistent production of active compounds at the intestinal target site
Opportunity
The researchers seek industry partners from nutraceuticals, functional foods, or metabolic health sectors for development collaboration and clinical validation.
